KNTE

Investor Moves

Name	Value	Action	Change	Price	Current Price
Jim SimonsRenaissance Technologies $-2.4K ExitQ2 2024 $2.4k -- --

Trade KNTE

About Kinnate Biopharma Inc.

Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.

CEO: Nima Farzan
IPO Date: Dec 3, 2020

Market Data

Open: $2.65
High: $2.68
Low: $2.64
Volume: 2.1M
Avg Volume: 417.6K
52W High: $7.19
52W Low: $1.04

Valuation

Market Cap: $125M
Enterprise Value: $71M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-100M
Revenue: $0
Net Income: $-113M
Cash: $57M
Debt: $3.2M

Events

EarningsMay 9

EPS est. -0.34 · actual -0.73